ISTH guidelines for antithrombotic treatment in COVID‐19

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, I...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of thrombosis and haemostasis Ročník 20; číslo 10; s. 2214 - 2225
Hlavní autori:	Schulman, Sam, Sholzberg, Michelle, Spyropoulos, Alex C., Zarychanski, Ryan, Resnick, Helaine E., Bradbury, Charlotte A., Connors, Jean Marie, Falanga, Anna, Iba, Toshiaki, Kaatz, Scott, Levy, Jerrold H., Middeldorp, Saskia, Minichiello, Tracy, Ramacciotti, Eduardo, Samama, Charles Marc, Thachil, Jecko, Broxmeyer, Lisa, International Society on Thrombosis and Haemostasis
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Inc 01.10.2022 Elsevier Limited John Wiley and Sons Inc
Predmet:	Aftercare anticoagulants Anticoagulants - adverse effects Coronaviruses COVID-19 critical illness Dosage Fibrinolytic Agents - adverse effects Heparin Heparin - adverse effects Heparin, Low-Molecular-Weight Hospitalization Humans Molecular weight Patient Discharge Patients platelet aggregation inhibitors Platelet Aggregation Inhibitors - adverse effects Recommendations and Guidelines Rivaroxaban Thromboembolism anticoagulants COVID‐19 critical illness platelet aggregation inhibitors COVID-19
ISSN:	1538-7836, 1538-7933, 1538-7836
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!